Trials / Not Yet Recruiting
Not Yet RecruitingNCT07446270
Efficacy of Tunlametinib in Combination With Anti-EGFR Monoclonal Antibody in Patients With RAS-Mutated Advanced Gastrointestinal Malignancies
A Cohort Clinical Study to Evaluate the Efficacy and Safety of Tunlametinib Combined With Anti-EGFR Monoclonal Antibody in Patients With RAS-mutated Advanced Gastrointestinal Malignancies
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- Sponsor
- Chinese PLA General Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Efficacy of Tunlametinib in Combination With Anti-EGFR Monoclonal Antibody in Patients With RAS-Mutated Advanced Gastrointestinal Malignancies
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Colorectal cancer: Tunlametinib + cetuximab β | Colorectal cancer: Tunlametinib 6/9mg bid+ cetuximab β 500mg/m2 |
| DRUG | Pancreatic cancer: Tunlametinib + cetuximab β | Pancreatic cancer: Tunlametinib 6/9mg+ cetuximab β 500mg/m2 |
| DRUG | Pancreatic cancer: Tunlametinib +Nimotuzumab | Pancreatic cancer: Tunlametinib 6/9mg bid +Nimotuzumab 400mg |
Timeline
- Start date
- 2026-03-03
- Primary completion
- 2027-10-30
- Completion
- 2028-10-30
- First posted
- 2026-03-03
- Last updated
- 2026-03-03
Source: ClinicalTrials.gov record NCT07446270. Inclusion in this directory is not an endorsement.